Short Wave

GLP-1 Pills Are On The Way. Here's What To Know

December 19, 2025

Key Takeaways Copied to clipboard!

  • The excitement surrounding GLP-1 drugs, currently available as weekly injections like Ozempic and Wagovi, is shifting toward new, experimental pill forms that promise better accessibility and potentially lower costs. 
  • The injectable GLP-1 drug semaglutide (the active ingredient in Ozempic/Wagovi) works by being chemically modified to last a week, whereas the natural hormone only lasts minutes. 
  • Two main oral drug candidates are emerging: a semaglutide pill from Novo Nordisk requiring an empty stomach for 30 minutes before eating, and a new compound pill called orphaglipron from Eli Lilly that does not have this restriction. 

Segments

GLP-1 Drugs Overview
Copied to clipboard!
(00:00:21)
  • Key Takeaway: GLP-1 injections like Ozempic and Wagovi are game-changers for weight loss but face barriers due to weekly injections and high monthly costs exceeding $1,000.
  • Summary: The current GLP-1 drugs, such as Ozempic (for diabetes) and Wagovi (for weight loss), require weekly injections. These injectables are life-changing for many seeking healthier weight management. However, their high sticker price, often over $1,000 monthly, and tricky insurance coverage present significant commitment and access issues.
Mechanism of GLP-1 Hormone
Copied to clipboard!
(00:04:47)
  • Key Takeaway: The natural GLP-1 hormone signals satiety immediately after eating but is very short-acting, lasting only a couple of minutes.
  • Summary: GLP-1 stands for glucagon-like peptide 1, a hormone naturally secreted upon food ingestion to signal fullness to the brain. This natural hormone is very short-acting, with its effect lasting only a couple of minutes in the body. Medications are chemically tweaked to last much longer than this natural duration.
Semaglutide Modification Explained
Copied to clipboard!
(00:05:24)
  • Key Takeaway: Semaglutide, the active ingredient in Ozempic/Wagovi, achieves a week-long half-life by removing amino acids and adding a fatty acid chain to resist natural enzyme breakdown.
  • Summary: Novo Nordisk modified the GLP-1 molecule by exchanging amino acids and adding a long fatty acid chain, preventing the enzyme that naturally degrades it from working quickly. This modification results in semaglutide having a half-life of one week, necessitating weekly injections for the current drugs.
Novo Nordisk Pill Development
Copied to clipboard!
(00:06:48)
  • Key Takeaway: The Novo Nordisk semaglutide pill uses an additive called SNAC to create a protective, foamy microenvironment in the stomach, allowing the peptide to be absorbed before being broken down.
  • Summary: The semaglutide pill requires being taken on an empty stomach and waiting 30 minutes before eating to ensure proper absorption. Scientists added a chemical abbreviated as SNAC, which creates a fizzy, protective environment around the tablet upon hitting the stomach wall. This allows the peptide to avoid immediate breakdown by stomach enzymes and enter the bloodstream.
Eli Lilly’s New Compound Pill
Copied to clipboard!
(00:09:22)
  • Key Takeaway: Eli Lilly’s oral candidate, orphaglipron, is a completely new compound, not a peptide, meaning it avoids the strict empty-stomach requirement of the Novo Nordisk pill.
  • Summary: Eli Lilly is developing a pill using a new active ingredient called orphaglipron, which is not a peptide like semaglutide. This structural difference means patients do not need to take it on an empty stomach and wait 30 minutes before eating. Orphaglipron showed an average weight loss of 12% over 72 weeks in one study.
Clinical Trial Process Length
Copied to clipboard!
(00:10:12)
  • Key Takeaway: Designing and running clinical trials for new medications like the Eli Lilly pill typically takes two to two and a half years to gather sufficient safety and efficacy data.
  • Summary: Designing clinical trials requires extensive planning, often taking about six months before the study begins. The process of recruiting participants, ensuring they complete all required visits, and finishing the study takes approximately two to two and a half years. Dr. Max Denning at Eli Lilly noted he never meets the patients as his role is to design and oversee the double-blind trials.
Pill Efficacy Comparison
Copied to clipboard!
(00:11:49)
  • Key Takeaway: The semaglutide pill from Novo Nordisk appears slightly more effective than Eli Lilly’s orphaglipron, achieving a 16-17% average weight reduction compared to orphaglipron’s 12%.
  • Summary: The 25-milligram semaglutide pill achieved a 16% to 17% average weight reduction over 64 weeks, performing similarly to the injectable Wagovi. In contrast, orphaglipron resulted in a 12% average weight loss at its highest dose over 72 weeks. While the injectable remains effective, the pill format offers a significant alternative for patients.
Cost and Affordability Outlook
Copied to clipboard!
(00:12:23)
  • Key Takeaway: Pills are generally cheaper to manufacture than injectables, potentially leading to lower sticker prices and better insurance coverage, with one deal suggesting a potential cash price of $149 per month.
  • Summary: The high out-of-pocket costs for injectables, often hundreds or thousands of dollars monthly, are a major barrier. Pills are typically easier and cheaper to manufacture, which could translate to lower downstream prices for consumers. A deal mentioned suggests a potential price point of $149 per month for consumers not using health insurance, indicating a possible path to greater access.